OSCAR產品信息
別稱：OSCAR,PIgR-3
物種：Human
屬性：Protein
標記：Unconjugated
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
OSCAR分子背景
OSCAR (Osteoclast-associated immunoglobulin-like receptor), also known as PIgR-3 (polymeric immunoglobulin-like receptor), is a type I transmembrane protein of the leukocyte receptor complex (LRC) family. OSCAR is specifically expressed by pre-osteoclasts and signals via FcR gamma. OSCAR co-stimulates one of the major FcR gamma -associated pathways required for osteoclastogenesis in vivo. Collagen type I and collagen type II serve as ligands for OSCAR. OSCAR binds to specific motifs within fibrillary collagens in the extracellular matrix (ECM). OSCAR promoted osteoclastogenesis in vivo, and its binding to the collagen motif led to signaling that increased numbers of osteoclasts in culture. OSCAR contains two immunoglobulin-like domains, D1 and D2. Direct binding assays on OSCAR molecules showed that D2, but not D1, is critical for collagen binding. OSCAR may contribute to the pathogenesis and severity of a number of diseases including osteoporosis, atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis.
關鍵字： OSCAR;OSCAR蛋白;OSCAR重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下擁有品牌ACROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。